CABA

Cabaletta Bio, Inc.

NasdaqGSUSDEQUITY DELAYED

3.18

▼ 0.01 (0.31%)

MARKET · —

Price

Open

3.24

Prev close

3.19

Day high

3.34

Day low

3.09

Volume

4.30M

Market cap

—

P/E (TTM)

—

52W range

1.40 – 4.23

Trailing performance

Price return · vs SPY

Returnvs SPY

+13.82% +15.2%

+15.07% +11.3%

-15.18% -18.3%

+7.56% -3.5%

YTD

+42.92% +30.6%

+98.10% +78.1%

-76.11% -150.3%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

2.91

+9.20% from price

SMA 20

2.82

+11.17% from price

SMA 50

2.88

+8.68% from price

SMA 100

3.12

+1.97% from price

SMA 200

2.87

+9.15% from price

EMA 12

2.94

+8.34% from price

EMA 26

2.88

+10.28% from price

EMA 50

2.93

+8.56% from price

RSI (14)

62.6

Neutral

MACD (12,26,9)

0.05

Hist 0.06

ATR (14)

0.18

5.75% of price

Realised vol 30D

51.1%

Annualised

Bollinger upper

3.12

20, 2σ

Bollinger lower

2.51

20, 2σ

50 / 200 cross

Golden

2.88 vs 2.87

Trend bias

Above 200

+9.15%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.76

More volatile than market

Correlation to SPY

0.23

Largely independent

Realised vol 30D

51.1%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-43.5%

Peak to trough

Max drawdown 5Y

-95.9%

Peak to trough

ATR 14

0.18

5.75% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 3.18

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

CABA · links out to the publisher

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update GlobeNewswire · 9d ago Kyverna Therapeutics Sinks 13%: Here’s Why 24/7 Wall St. · 43d ago How Cabaletta Bio (CABA) Is Turning Rese-cel Enrollment and New Financing Into a Clearer Autoimmune Cell Therapy Setup Insider Monkey · 66d ago FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases Exec Edge · 74d ago Cathie Wood's ARK Invest Joins Cellares' $277 Million Series D Business Wire · 74d ago Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases Insider Monkey · 76d ago Cabaletta Bio's Rese-cel Shows Potential in Treating Autoimmune Diseases MT Newswires · 80d ago Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress GlobeNewswire · 80d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.